India's New Drug Rules Explained: Medicine Pricing, Stem Cell Therapies Get Major Regulatory Update
India's New Drug Rules Explained: Medicine Pricing, Stem Cell Therapies Get Major Regulatory Update Reported By, Last Updated: July 03, 2026, 07:44 IST One amendment
India's New Drug Rules Explained: Medicine Pricing, Stem Cell Therapies Get Major Regulatory Update Reported By, Last Updated: July 03, 2026, 07:44 IST One amendment changes how essential medicine prices are regulated. The other formally brings stem cell products, gene therapies and xenografts under India's drug laws. Rapid Read One of the biggest changes is that the government can now notify different ceiling or retail prices for the same medicine depending on its pack size, packaging or dosage form. (Representational image) The Centre has notified two significant amendments to India’s drug regulatory framework – one changing how the prices of medicines are regulated and the other formally bringing stem cell products, gene therapies and xenografts under the country’s drug laws. One deals with the prices patients pay for essential medicines, while the other concerns some of the most advanced treatments now being developed for diseases such as cancer and rare genetic disorders. But together, they update two important parts of India’s drug regulation – one governing affordability and the other governing innovation. So what changes for drugmakers? The first amendment, notified by the Ministry of Chemicals and Fertilizers on June 30, modifies the Drugs (Prices Control) Order (DPCO), 2013 — the law through which the drug regulator Pharmaceutical Pricing Authority (NPPA) fixes ceiling prices of essential medicines. The amendment changes how those prices are implemented and enforced. For years, the industry has argued that certain provisions of the DPCO created practical difficulties. Manufacturers faced different interpretations by regulators, uncertainty over pricing of different pack sizes, and disputes over liability when older stock remained in the market after a new ceiling price was notified.
“…case of any drug for which a ceiling price or retail price has been fixed, the Government may fix and notify separate ceiling price or retail price on an application made by the manufacturer or otherwise, for such drug with specified therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack, namely, liquid, gaseous or any other form, in the unit dosage…" The latest amendment attempts to address some of these issues while tightening compliance in others. One of the biggest changes is that the government can now notify different ceiling or retail prices for the same medicine depending on its pack size, packaging or dosage form. The amendment states that the government may “fix and notify separate ceiling price or retail price" after considering the type of packaging, pack size or dosage form. This gives regulators greater flexibility where medicines are sold in different presentations. Another important change concerns overcharging. Earlier, manufacturers could face liability even for stock that had already moved into the distribution chain before a revised ceiling price came into effect. The amended rules now provide some relief. They state that “the liability of the manufacturer for overcharging shall be restricted to the quantity of stock traded through the distributor or retailer found to have effected such overcharging." In effect, liability will be linked to the stock actually found to have been sold above the notified price, provided manufacturers can demonstrate that they took the required steps to communicate the revised prices. The amendment also simplifies procedures for existing manufacturers. Companies launching the same new drug within twelve months of the first retail price fixation will no longer have to seek fresh approval from the NPPA.
The BriefWire